Latest US Food and Drug Administration Stories
SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 6, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc.
SAN DIEGO, Aug. 3, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
WILMINGTON, Del., July 28 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS). (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) The Advisory...
ANAHEIM, Calif., July 27 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that it has received clearance from the US Food and Drug Administration (FDA) to market the first-ever, rapid point-of-care, lab-quality blood test for measuring total bilirubin (tBili) in newborns.
American scientists have developed â€œartificial bloodâ€ that could soon be used to treat soldiers who are wounded during battle.
AMSTERDAM, July 8 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma announced today that it has received approval for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to start the pivotal clinical study for its product ATIR(TM) in the United States.
WAYNE, N.J., June 17 /PRNewswire/ -- In a June 16, 2010 proceeding before Judge Virginia Kendall in US Federal Court in the Northern District of Illinois, Teva Pharmaceuticals USA Inc.
EAST HANOVER, N.J., June 10 /PRNewswire/ -- Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease.
EAST HANOVER, N.J., June 5 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results from a Phase II study show AfinitorÂ® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS) (1,2).
SAN DIEGO, June 2, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
- A volcanic mudflow.